Silibinin can induce differentiation as well as enhance vitamin D 3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors

Hematological Oncology

Volumn 28, Issue 3, 2010, Pages 124-132

  Zhang, Jing ^a   Harrison, Jonathan S ^b   Uskokovic, Milan ^c   Danilenko, Michael ^d   Studzinski, George P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c Bioxell Inc   (United States)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Acute myeloid leukaemia; c Jun; C EBP; Differentiation; Silibinin

Indexed keywords

1,25 DIHYDROXY 16 ENE 20 CYCLOPROPYL 24 OXO CHOLECALCIFEROL; 1,25 DIHYDROXY 16 ENE 20 CYCLOPROPYL CHOLECALCIFEROL; BXL 0062; BXL 0143; CCAAT ENHANCER BINDING PROTEIN; COLECALCIFEROL; RETINOID X RECEPTOR ALPHA; SILIBININ; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; SILYMARIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MONOCYTE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; CELL DIFFERENTIATION; CHOLECALCIFEROL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, CALCITRIOL; RETINOID X RECEPTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SILYMARIN; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 77957298685     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.929     Document Type: Article

References (52)

1. Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol 2003; 3(4): 338-343.
2. Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev 2004; 30(3): 237-247.
3. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as frontline therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112(5): 1638-1645.
4. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008; 22(4): 808-818.
5. Griffin JD. The use of monoclonal antibodies in the characterization of myeloid leukemias. Hematol Pathol 1987; 1(2): 81-91.
6. Nishioka C, Ikezoe T, Yang J, Gery S, Koeffler HP, Yokoyama A. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells. Int J Cancer 2009.
7. Lancet JE, Karp JE. Novel postremission strategies in adults with acute myeloid leukemia. Curr Opin Hematol 2009; 16(2): 105-111.
8. Studzinski GP, Wang X, Ji Y, et al. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. J Steroid Biochem Mol Biol 2005; 97(1-2): 47-55.
9. Flynn PJ, Miller WJ, Weisdorf DJ, Arthur DC, Brunning R, Branda RF. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood 1983; 62(6): 1211-1217.
10. Fontana JA, Rogers JS 2nd, Durham JP. The role of 13 cis-retinoic acid in the remission induction of a patient with acute promyelocytic leukemia. Cancer 1986; 57(2): 209-217.
11. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85(10): 2643-2653.
12. Abe E, Miyaura C, Sakagami H, et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1981; 78(8): 4990-4994. (Pubitemid 12225607)
13. Munker R, Kobayashi T, Elstner E, et al. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 1996; 88(6): 2201-2209.
14. Wang Q, Harrison JS, Uskokovic M, Kutner A, Studzinski GP. Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. Leukemia 2005; 19(10): 1812-1817.
15. Waxman S. Differentiation therapy in acute myelogenous leukemia (non-APL). Leukemia 2000; 14(3): 491-496.
16. Koeffler HP, Hirji K, Itri L. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985; 69(12): 1399-1407.
17. Wieder R, Novick SC, Hollis BW, et al. Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies. Invest New Drugs 2003; 21(4): 445-452.
18. Chan JS, Beer TM, Quinn DI, et al. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int 2008; 102(11): 1601-1606.
19. Danilenko M, Studzinski GP. Enhancement by other compounds of the anti-cancer activity of vitamin D(3) and its analogs. Exp Cell Res 2004; 298(2): 339-358.
20. Chu YF, Sun J, Wu X, Liu RH. Antioxidant and antiproliferative activities of common vegetables. J Agric Food Chem 2002; 50(23): 6910-6916. (Pubitemid 35253192)
21. Lopez-Velez M, Martinez-Martinez F, Del Valle-Ribes C. The study of phenolic compounds as natural antioxidants in wine. Crit Rev Food Sci Nutr 2003; 43(3): 233-244.
22. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev 2009; 18(1): 13-25.
23. Shabtay A, Sharabani H, Barvish Z, et al. Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia. Oncology 2008; 75(3-4): 203-214.
24. Sharabani H, Izumchenko E, Wang Q, et al. Cooperative anti-tumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia. Int J Cancer 2006; 118(12): 3012-3021.
25. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002; 62(11): 3063-3069.
26. Bhatia N, Zhao J, Wolf DM, Agarwal R. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett 1999; 147(1-2): 77-84.
27. Singh RP, Deep G, Chittezhath M, et al. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 2006; 98(12): 846-855.
28. Son YG, Kim EH, Kim JY, et al. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res 2007; 67(17): 8274-8284.
29. Li L, Gao Y, Zhang L, Zeng J, He D, Sun Y. Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett 2008; 272(1): 61-69.
30. Chittezhath M, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol Cancer Ther 2008; 7(7): 1817-1826.
31. Kim KW, Choi CH, Kim TH, Kwon CH, Woo JS, Kim YK. Silibinin inhibits glioma cell proliferation via Ca2+/ROS/MAPK-dependent mechanism in vitro and glioma tumor growth in vivo. Neurochem Res 2009; 34(8): 1479-1490.
32. Singh RP, Raina K, Deep G, Chan D, Agarwal R. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 2009; 15(2): 613-621.
33. Velmurugan B, Singh RP, Tyagi A, Agarwal R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res (Phila Pa) 2008; 1(5): 376-384.
34. Lin CJ, Sukarieh R, Pelletier J. Silibinin inhibits translation initiation: implications for anticancer therapy. Mol Cancer Ther 2009; 8(6): 1606-1612.
35. Garcia-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009; 28(3): 313-324.
36. Tyagi A, Singh RP, Ramasamy K, et al. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila Pa) 2009; 2(1): 74-83.
37. Kang SN, Lee MH, Kim KM, Cho D, Kim TS. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochem Pharmacol 2001; 61(12): 1487-1495.
38. 3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res 2003; 63(6): 1325-1332.
39. 3 in induction of leukemia HL60 cell differentiation through the JNK/AP-1/Egr-1 pathway. J Cell Physiol 2005; 204(3): 964-974.
40. Laverny G, Penna G, Uskokovic M, et al. Synthesis and anti-inflammatory properties of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl- vitamin D3. J Med Chem 2009; 52(8): 2204-2213.
41. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33(4): 451-458.
42. Zhang J, Posner GH, Danilenko M, Studzinski GP. Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway. J Steroid Biochem Mol Biol 2007; 105(1-5): 140-149.
43. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162(1): 156-159.
44. Kang SN, Lee MH, Kim KM, Cho D, Kim TS. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochem Pharmacol 2001; 61(12): 1487-1495.
45. Danilenko M, Wang Q, Wang X, Levy J, Sharoni Y, Studzinski GP. Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Res 2003; 63(6): 1325-1332.
46. Kolla SS, Studzinski GP. Resolution of multiple AP-1 complexes in HL-60 cells induced to differentiate by 1,25-dihydroxyvitamin D3. J Cell Physiol 1993; 156(1): 63-71.
47. Wang X, Studzinski GP. The requirement for and changing composition of the activating protein-1 transcription factor during differentiation of human leukemia HL60 cells induced by 1,25-dihydroxyvitamin D3. Cancer Res 2006; 66(8): 4402-4409.
48. Ji Y, Studzinski GP. Retinoblastoma protein and CCAAT/enhancer-binding protein beta are required for 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL60 cells. Cancer Res 2004; 64(1): 370-377.
49. Marcinkowska E, Garay E, Gocek E, Chrobak A, Wang X, Studzinski GP. Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3. Exp Cell Res 2006; 312(11): 2054-2065.
50. Koschmieder S, Agrawal S, Radomska HS, et al. Decitabine and vitamin D3 differentially affect hematopoietic transcription factors to induce monocytic differentiation. Int J Oncol 2007; 30(2): 349-355.
51. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 2007; 6(10): 2696-2707.
52. Bang CI, Paik SY, Sun DI, Joo YH, Kim MS. Cell growth inhibition and down-regulation of survivin by silibinin in a laryngeal squamous cell carcinoma cell line. Ann Otol Rhinol Laryngol 2008; 117(10): 781-785.